Skip to content
Screener

McKesson MCK Restricted Cash

Restricted Cash at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$8.64M-10.4%
Viatris logo
ViatrisVTRS
$3.5M+150%
Medline, Inc. logo
Medline, Inc.MDLN
$2M—
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$155M+150%
Merck & Co. logo
Merck & Co.MRK
$42M-36.4%
Omnicell logo
OmnicellOMCL
$30.6M-5.8%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$101.38B+21.2%
Enterprise value$109.1B+18.3%
P/E22.1×-4.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%—
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The source filing: McKesson’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234

FAQ

What is McKesson's restricted cash?
McKesson (MCK) reported restricted cash of $92M in Q2 2026.
How has McKesson's restricted cash changed year-over-year?
McKesson's restricted cash decreased by 65.3% year-over-year, from $265M to $92M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about McKesson's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude